NCT04149639已完成不适用
An Open-label Study to Investigate the Effectiveness of a LifeSeasons NeuroQ Supplement in Addition to Four Bredesen Recommended Lifestyle Changes to Improve Cognitive Function in Healthy Adults Who Have One or More Risk Factors for Cognitive Decline
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 4
- 主要终点
- Change in cognition as assessed by change in Neurocognitive Index (NCI) score from CNS-Vital Signs (CNS-VS) panel from screening to end-of-study.
研究概览
简要总结
The objective of this study is to evaluate the efficacy of a NeuroQ supplement designed by Dr. Bredesen to complement his Lifestyle modification protocol. Eligible participants will be expected to consume the NeuroQ supplement and are recommended to make lifestyle changes based on Dr. Bredesen's protocol. Forty participants are expected to enroll into the study, completing study assessments at check in visits days 30 and 60, and at the end of study visit on day 90. A brief follow up phone call will be conducted approximately 30 days after study completion to ask participants if they have continued using the lifestyle changes and if they have purchased and continued to consume the NeuroQ supplement.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 45 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males and females 45 years of age or older with one or more of the following risk factors for cognitive decline:
- •Self-reported genetic risk factor of Alzheimer's Disease or dementia as confirmed by Apolipoprotein 4 genetic testing
- •Self-reported family history of Alzheimer's Disease or dementia in a first-degree relative
- •Self-reported lifestyle risk factor: sedentary lifestyle; poor dietary habits (e.g. insufficient consumption of fruits and vegetables for necessary nutrients); poor social support network (e.g. majority of evenings and weekends are spent in isolation); poor stress management skills (e.g. binge eating habits or performing harmful activities during periods of stress); poor sleep habits; metabolic syndrome
- •Exception: Individuals 60 years of age or older may be enrolled without any of the above risk factors.
- •BMI between 18.5 and 32.5 kg/m2
- •Female participants are not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal (natural or surgically) for at least 1 year prior to screening
- •Females of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
- •Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
- •Double-barrier method
- •Intrauterine devices
- •Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
- •Vasectomy of partner at least 6 months prior to screening
- •Self-reported as non-smoker or user of any nicotine-containing products
- •Absence of dementia or other significant cognitive impairment as assessed by Mini Mental State Exam-2 Standard Version (MMSE-2) score ≥24
- •Participants who test between the 24-75th percentile in the in one or more domains in the NCI
- •Low frequency of depressed mood as assessed by PHQ-9 score of 4 or less
- •Agree to avoid caffeine consumption 24 hours prior to in-clinic visits
- •Agree to avoid alcohol consumption 24 hours prior to in-clinic visits
- •Healthy as determined by medical history and laboratory results as assessed by QI
排除标准
- •Women who are pregnant, breast feeding, or planning to become pregnant during the trial
- •Allergy, sensitivity, or intolerance to the investigational product's (IP) active or inactive ingredients
- •Self-reported confirmation of neuropsychological condition and/or cognitive impairment that, in the QI's opinion, could interfere with study participation. For e.g.:
- •Schizophrenia, bipolar disorder, post-traumatic stress disorder, brain injury, neurodegenerative disease, infections, insomnia
- •Participants with vitamin deficiencies affecting cognition:
- •Magnesium
- •Cobalamin (Vitamin B12)
- •Folate below the normal clinical ranges, as assessed by the QI
- •Participants who test below the 24th percentile or above the 75th percentile in all domains in the NCI.
- •Current use of prescribed medications listed in Section 8.3.
- •Current use of over-the-counter medications, supplements, foods and/or drinks listed as concomitant medications.
- •Unstable metabolic disease or chronic diseases as assessed by the QI
- •Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
- •Type II diabetes. Treatment on a stable dose of medication may be considered by the QI on a case by case basis
- •Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case by case basis
- •Major surgery in the past 3 months or individuals who have planned surgery during the course of the trial. Participants with minor surgery will be considered on a case-by-case basis by the QI
- •Cancer, except skin cancers completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
- •Individuals who are immune-compromised
- •Verbal confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis
- •History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones symptom free for 6 months
- •Verbal confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
- •Current or history of any significant diseases of the gastrointestinal tract
- •Verbal confirmation of blood/bleeding disorders
- •Self-reported chronic use of cannabinoid products or currently taking medical cannabinoid products containing >0.3% tetrahydrocannabinol
- •Alcohol or drug abuse within the last 12 months
- •High alcohol intake (>2 drinks per day or >10 standard drinks per week)
- •Blood donation 30 days prior to screening, during the study, or a planned donation within 30-days of the last study visit
- •Participation in other clinical research trials 30 days prior to screening
- •Individuals who are unable to give informed consent
- •Any other active or unstable medical condition, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
结局指标
主要结局
Change in cognition as assessed by change in Neurocognitive Index (NCI) score from CNS-Vital Signs (CNS-VS) panel from screening to end-of-study.
时间窗: 90-135 days
The Neurocognitive index is an average score derived from the domain scores or a general assessment of the overall neurocognitive status of the participant. The scores range from less than 70 (very low) to above 110 (above average). A higher score means higher neurocognitive function and higher capacity.
次要结局
- Change in individual Central Nervous System-Vital Signs (CNS-VS) domain - psychomotor speed from screening to end-of-study(90-135 days)
- Change in Neurocognitive Index (NCI) individual domains from screening to end-of-study in participants who are compliant with lifestyle modification only(90-135 days)
- Change in individual Central Nervous System-Vital Signs (CNS-VS) domain - verbal memory from screening to end-of-study(90-135 days)
- Change in individual Central Nervous System-Vital Signs (CNS-VS) domain - visual memory from screening to end-of-study(90-135 days)
- Change in individual Central Nervous System-Vital Signs (CNS-VS) domain - processing speed from screening to end-of-study(90-135 days)
- Change in Mini Mental State Exam Version 2 (MMSE-2) score from screening to end-of study.(90-135 days)
- Change in Neurocognitive Index (NCI) individual domains from screening to end-of study in participants who are fully compliant with supplementation and lifestyle modification(90-135 days)
- Change in Neurocognitive Index (NCI) individual domains from screening to end-of-study in participants who are compliant with supplementation only(90-135 days)
- Change in individual Central Nervous System-Vital Signs (CNS-VS) domain - composite memory from screening to end-of-study(90-135 days)
- Change in individual Central Nervous System-Vital Signs (CNS-VS) domain - reaction time from screening to end-of-study(90-135 days)
- Change in individual Central Nervous System-Vital Signs (CNS-VS) domain - complex attention from screening to end-of-study(90-135 days)
- Change in individual Central Nervous System-Vital Signs (CNS-VS) domain - simple attention from screening to end-of-study(90-135 days)
- Change in individual Central Nervous System-Vital Signs (CNS-VS) domain - cognitive flexibility from screening to end-of-study(90-135 days)
- Change in individual Central Nervous System-Vital Signs (CNS-VS) domain - executive function from screening to end-of-study(90-135 days)
- Change in individual Central Nervous System-Vital Signs (CNS-VS) domain - motor speed from screening to end-of-study(90-135 days)
- Number of participants motivated to make lasting changes to their lifestyle at end-of-study.(90-120 days)
研究者
研究点 (4)
Loading locations...
相似试验
招募中
不适用
Quantitative and Repetitive TMS in ALS - Recruiting for Stage 2Amyotrophic Lateral SclerosisNCT05983211Sunnybrook Health Sciences Centre15
已完成
2 期
A Study to Investigate the Safety and Efficacy of NeuroQ on Cognitive Function in Health Adults with Self-Reported Memory ProblemsHealthySelf-reported Memory ProblemsNCT06672094LifeSeasons Inc.40
已完成
4 期
Functional Bioactive Supplement Effect in Lost Weight TreatmentObesity and OverweightNCT02024425Instituto de Investigación Hospital Universitario La Paz109
已完成
不适用
Nutraceutical Supplement With Standardized Botanicals in Males With Thinning HairHair ThinningNCT05339958Nutraceutical Wellness Inc.112
已完成
不适用
Brain Imaging StudyBrain HealthNCT02439983Pharmanex68